Globus Medical, Inc. $GMED Shares Sold by Madison Asset Management LLC

Posted by George Bondi on May 15th, 2026

Madison Asset Management LLC cut its holdings in Globus Medical, Inc. (NYSE:GMED – Free Report) by 43.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,151 shares of the medical device company’s stock after selling 11,599 shares during the quarter. Madison Asset Management LLC’s holdings in Globus Medical were worth $1,323,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of GMED. Advisory Services Network LLC acquired a new position in Globus Medical in the third quarter valued at $26,000. EverSource Wealth Advisors LLC increased its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the period. SBI Securities Co. Ltd. increased its stake in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the period. First Horizon Corp acquired a new position in Globus Medical in the third quarter valued at $31,000. Finally, Parallel Advisors LLC increased its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on GMED. Needham & Company LLC lifted their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wells Fargo & Company dropped their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Royal Bank Of Canada lifted their target price on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Truist Financial set a $115.00 target price on shares of Globus Medical in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.36.

Read Our Latest Research Report on GMED

Insider Buying and Selling at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 18.38% of the stock is currently owned by insiders.

Globus Medical Stock Up 2.2%

Shares of NYSE:GMED opened at $77.25 on Friday. The company has a market cap of $10.45 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 1.56 and a beta of 1.00. The firm’s 50-day simple moving average is $88.05 and its 200-day simple moving average is $87.16. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current year.

Globus Medical Company Profile

(Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.